Neurocritical Care News

The FDA has cleared Abbott’s laboratory blood test for concussion, making it the first commercially available test of its kind, according to a company press release.

The FDA has granted 510(k) clearance to Neuro20 Technologies for its Neuro20 Pro System, a wearable whole-body electrical muscle stimulator suit, software and operating system for neuromuscular injuries and disease.

SAN DIEGO — A newly developed auditory-based test could assess and monitor cognitive function in previously untestable patients who are severely affected by MS, according to a poster at ACTRIMS 2023.

SAN DIEGO — Evidence over the past 10 years supports the role of Epstein-Barr virus in the development of MS, according to a presenter at ACTRIMS 2023.

Viz.ai announced a collaboration with BIOS Clinical Trials Coordinating Center at Johns Hopkins University to facilitate patient enrollment for the NIH-funded Biomarker and Edema Attenuation in Intracerebral Hemorrhage study.

Teva Pharmaceuticals announced FDA approval of Austedo XR, a once-daily, extended-release formulation for adults with tardive dyskinesia and chorea associated with Huntington’s disease.

Ashvattha Therapeutics announced that the first patient has been enrolled in a phase 1/2 study to evaluate the ability of an imaging agent to cross the blood-brain barrier and target key markers of neuroinflammation.

Medical technology company Imperative Care has announced the formation of Kandu Health, a digital health startup that aims to advance stroke recovery and post-acute stroke care through education, resources and guidance.

Nova Mentis Life Science Corp. has received an exemption under Section 56 of the Health Canada Controlled Drugs and Substances Act to advance a phase 2a clinical trial examining oral microdose psilocybin therapy for fragile X syndrome.

The FDA has granted orphan drug designation to Avidity Biosciences Inc. for AOC 1020, its novel RNA therapeutic to treat facioscapulohumeral muscular dystrophy.